Role of Linagliptin in Type 2 Diabetes Mellitus Therapy: An Indian Perspective

Dr RAKESH SAHAY; Dr GANAPATHI BANTWAL; Dr SHUBHANKAR CHOWDHARY

doi:10.59793/ijcp.v34i7.736

Authors

Dr RAKESH SAHAY Consultant Endocrinologist and Diabetologist Professor and Head, Dept. of Endocrinology, Osmania Medical College and Osmania General Hospital, Hyderabad, Telangana, India
Dr GANAPATHI BANTWAL † Professor and Head, Dept. of Endocrinology, St. John's Medical College Hospital, Bengaluru, Karnataka, India
Dr SHUBHANKAR CHOWDHARY ‡ Professor and Head, Dept. of Endocrinology, Post Graduate Medical Education & Research and SSKM Hospital, Kolkata, West Bengal, India

DOI:

https://doi.org/10.59793/ijcp.v34i7.736

Keywords:

Linagliptin,, DPP-4 inhibitors,, , type 2 diabetes mellitus,, gliptins

Abstract

Given the rising prevalence and significant health and economic burdens associated with type 2 diabetes mellitus (T2DM)
globally, especially in low- and middle-income countries, exploring effective treatment options is crucial. In this review, we
have reviewed the role of linagliptin therapy in managing T2DM in the Indian context. The review specifically delves into
the pharmacokinetic and pharmacodynamic properties of linagliptin, emphasizing its potential benefits in the context of the
unique characteristics of Asian T2DM patients. The study provides valuable insights into the strategic use of linagliptin in
the treatment landscape of T2DM, offering a comprehensive and all-encompassing approach to its clinical implications in
various patient settings.